A cerebellopontine angle metastatis of a male breast cancer: Case report

Bertal, A.; Mawhoub, Sara; Makhchoune, Marouane; Ibahiouin, K.; Lakhdar, Abdelhakim; Tahrir, Y.

doi:10.1016/j.amsu.2022.103421

Cited by 4 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Male breast cancer with brain metastasis is an extremely uncommon condition, with even rarer depiction at the level of the cerebellopontine angle, which can manifest with acute onset and rapid progression of symptoms: deterioration of the level of consciousness and intracranial hypertension, as explained by Tahrir [ 36 ] in a study describing a triple negative male breast cancer patient.…”

Section: Resultsmentioning

confidence: 99%

An Update on the General Features of Breast Cancer in Male Patients—A Literature Review

et al. 2022

View full text Add to dashboard Cite

Male breast cancers are uncommon, as men account for less than 1 percent of all breast carcinomas. Among the predisposing risk factors for male breast cancer, the following appear to be significant: (a) breast/chest radiation exposure, (b) estrogen use, diseases associated with hyper-estrogenism, such as cirrhosis or Klinefelter syndrome, and (c) family health history. Furthermore, there are clear familial tendencies, with a higher incidence among men who have a large number of female relatives with breast cancer and (d) major inheritance susceptibility. Moreover, in families with BRCA mutations, there is an increased risk of male breast cancer, although the risk appears to be greater with inherited BRCA2 mutations than with inherited BRCA1 mutations. Due to diagnostic delays, male breast cancer is more likely to present at an advanced stage. A core biopsy or a fine needle aspiration must be performed to confirm suspicious findings. Infiltrating ductal cancer is the most prevalent form of male breast cancer, while invasive lobular carcinoma is extremely uncommon. Male breast cancer is almost always positive for hormone receptors. A worse prognosis is associated with a more advanced stage at diagnosis for men with breast cancer. Randomized controlled trials which recruit both female and male patients should be developed in order to gain more consistent data on the optimal clinical approach.

show abstract

Section: Resultsmentioning

confidence: 99%

An Update on the General Features of Breast Cancer in Male Patients—A Literature Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Obecność przerzutów do ośrodkowego układu nerwowego (OUN) raportuje się w około 20% wszystkich przypadków BC. Przerzuty MBC do OUN są rzadkie, mogą manifestować się 29 jednak nagłym początkiem i szybką progresją objawów, takich jak pogorszenie poziomu świadomości czy nadciśnienie wewnątrzczaszkowe [14]. Sugeruje się, iż płeć męska jest niezależnym czynnikiem ryzyka gorszego rokowania oraz krótszych współczynników przeżycia w przypadku obecności przerzutów do OUN [15].…”

Section: Diagnostykaunclassified

Male breast cancer - a review on risk factors, tumor characteristics, diagnostics and treatment

Zielińska

Aleksandrowicz

Zarankiewicz

et al. 2022

J Educ Health Sport

View full text Add to dashboard Cite

Introduction and purpose: Male breast cancer (MBC) is estimated to less than 1% of all breast cancer cases worldwide. A lifetime risk of developing MBC amounts to 1:1000. The data on breast cancer in men is limited. This review aims to analyze information on risk factors, diagnostics and treatment in men suffering from breast cancer. Material and method: This review was based on available data collected in PubMed and published in the years 2001-2022. The research was done by looking through keywords as follows: “breast cancer”, “male breast cancer”, “risk factors” and “treatment”. Results: Male breast cancer usually manifests as a painless, retroareolar mass in the breast. Risk factors include advanced age, hormonal imbalance, exposure to radiation and a positive family history. A significant risk increase in MBC development occurs in BRCA2, CHEK2, PALB2 and ATM genes mutations. G2 ductal carcinoma with no special type is most often diagnosed. Dominating subtype is luminal A cancer, while HER2 protein overexpression is extremely rare. Radical mastectomy or breast conserving therapy remain surgical therapeutic options. The most preferred endocrine therapy is tamoxifen. The choice of chemotherapy in men is based on the same criteria as in women. Conclusions: Delayed diagnosis and tumor characteristics are associated with a much worse prognosis for men compared to women. Therefore, further clinical research is crucial in order to improve the diagnostic possibilities and treatment targeted at men with this type of cancer.

show abstract

Omission of adjuvant radiotherapy in low-risk elderly males with breast cancer

Vo,

Ladbury,

Yoon

et al. 2024

Breast Cancer

View full text Add to dashboard Cite

Purpose Randomized clinical trials demonstrate that lumpectomy + hormone therapy (HT) without radiation therapy (RT) yields equivalent survival and acceptable local–regional outcomes in elderly women with early-stage, node-negative, hormone-receptor positive (HR +) breast cancer. Whether these data apply to men with the same inclusion criteria remains unknown. Methods The National Cancer Database was queried for male patients ≥ 65 years with pathologic T1-2N0 (≤ 3 cm) HR + breast cancer treated with breast-conserving surgery with negative margins from 2004 to 2019. Adjuvant treatment was classified as HT alone, RT alone, or HT + RT. Male patients were matched with female patients for OS comparison. Survival analysis was performed using Cox regression and Kaplan − Meier method. Inverse probability of treatment weighting (IPTW) was applied to adjust for confounding. Results A total of 523 patients met the inclusion criteria, with 24.4% receiving HT, 16.3% receiving RT, and 59.2% receiving HT + RT. The median follow-up was 6.9 years (IQR: 5.0–9.4 years). IPTW-adjusted 5-yr OS rates in the HT, RT, and HT + RT cohorts were 84.0% (95% CI 77.1–91.5%), 81.1% (95% CI 71.1–92.5%), and 93.0% (95% CI 90.0–96.2%), respectively. On IPTW-adjusted MVA, relative to HT, receipt of HT + RT was associated with improvements in OS (HR: 0.641; p = 0.042). RT alone was not associated with improved OS (HR: 1.264; p = 0.420). Conclusion Among men ≥ 65 years old with T1-2N0 HR + breast cancer, RT alone did not confer an OS benefit over HT alone. Combination of RT + HT demonstrated significant improvements in OS. De-escalation of treatment through omission of either RT or HT at this point should be done with caution.

show abstract

A cerebellopontine angle metastatis of a male breast cancer: Case report

Cited by 4 publications

References 18 publications

An Update on the General Features of Breast Cancer in Male Patients—A Literature Review

An Update on the General Features of Breast Cancer in Male Patients—A Literature Review

Male breast cancer - a review on risk factors, tumor characteristics, diagnostics and treatment

Omission of adjuvant radiotherapy in low-risk elderly males with breast cancer

Contact Info

Product

Resources

About